Completed PHASE4 INTERVENTIONAL 1-arm NCT02077699

Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study

Valutazione Dell'Efficacia Di Una Preparazione Commerciale A Base Di Lactobacillus Casei Dg Nella Riduzione Della Sintomatologia Dolorosa Associata Alla Sindrome Dell' Intestino Irritabile (Sii). Studio Clinico Pilota. (Official Title in Italian Language)

Sponsor: SOFAR S.p.A.

Conditions Irritable Bowel Syndrome

Interventions Lactobacillus casei DG

Updated 5 times since 2017 Last updated: Nov 27, 2014 Started: Mar 31, 2012 Primary completion: Jun 30, 2014 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Irritable Bowel Syndrome, this trial is completed. The trial is conducted by SOFAR S.p.A. and has accumulated 5 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SOFAR S.p.A.

Data source: SOFAR S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Roma, Italy